X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
TB006 is a humanized monoclonal antibody that, by blocking Galectin-3, the root cause of neuroinflammation and aggregation of Aβ and pTau and other pathogenic factors, has the potential to improve cognition and functioning of patients with alzheimer's disease (AD).
Lead Product(s): TB006
Therapeutic Area: Neurology Product Name: TB006
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 28, 2023
Details:
TB006 is a humanized monoclonal antibody that, by blocking Galectin-3, the root cause of neuroinflammation and aggregation of Aβ and pTau and other pathogenic factors, has the potential to improve cognition and functioning of patients with alzheimer's disease (AD).
Lead Product(s): TB006
Therapeutic Area: Neurology Product Name: TB006
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 14, 2023
Details:
TB006 is a humanized monoclonal antibody that, based on preclinical data and early clinical studies, has the potential to improve cognition and functioning of patients with Alzheimer’s disease (AD).
Lead Product(s): TB006
Therapeutic Area: Neurology Product Name: TB006
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 18, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
